Pressing The Reset Button: Stem Cell Transplant For Relapsing-Remitting Multiple Sclerosis
Faculty Advisor Name
Dr. Abby Massey
Department
Department of Health Professions
Description
Abstract:
Objective: To perform an analysis of studies that assessed if autologous hematopoietic stem cell transplant (aHSCT) is more efficacious than monoclonal antibody (mAb) disease modifying treatment (DMT) in reducing Expanded Disability Score Status (EDSS) and thereby slowing disease progression in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Design: Systematic literature review. Methods: Initial systematic database searches were performed through PubMed. Secondary searches were performed via hand-searching techniques of multiple sources, such as the Journal of the American Medical Association (JAMA), the British Journal of Medicine (BMJ), and the Neurology Journal. Access was provided through the Library at James Madison University. Inclusion criteria were: original research performed within the last five years, and treatment regimens of aHSCT and monoclonal antibody (mAb) therapy in patients with RRMS. Results: The Burt et al. study found that aHSCT prolonged progression of RRMS compared to DMT treatment. Zhukovsky et al. determined aHSCT treatment promoted "no evidence of disease activity" compared to DMTs. Kalincik et al. noted aHSCT therapy was superior in decreasing the severity and frequency of relapses compared to moderate-efficacy DMTs and one high-efficacy DMT; however, aHSCT was found to be non-inferior to a newer high-efficacy DMT. Conclusion: all three studies demonstrated the efficacious benefits of aHSCT therapy for patients with highly active RRMS, though further research is required for more direct comparisons to mAbs more recently approved for RRMS.
Pressing The Reset Button: Stem Cell Transplant For Relapsing-Remitting Multiple Sclerosis
Abstract:
Objective: To perform an analysis of studies that assessed if autologous hematopoietic stem cell transplant (aHSCT) is more efficacious than monoclonal antibody (mAb) disease modifying treatment (DMT) in reducing Expanded Disability Score Status (EDSS) and thereby slowing disease progression in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS). Design: Systematic literature review. Methods: Initial systematic database searches were performed through PubMed. Secondary searches were performed via hand-searching techniques of multiple sources, such as the Journal of the American Medical Association (JAMA), the British Journal of Medicine (BMJ), and the Neurology Journal. Access was provided through the Library at James Madison University. Inclusion criteria were: original research performed within the last five years, and treatment regimens of aHSCT and monoclonal antibody (mAb) therapy in patients with RRMS. Results: The Burt et al. study found that aHSCT prolonged progression of RRMS compared to DMT treatment. Zhukovsky et al. determined aHSCT treatment promoted "no evidence of disease activity" compared to DMTs. Kalincik et al. noted aHSCT therapy was superior in decreasing the severity and frequency of relapses compared to moderate-efficacy DMTs and one high-efficacy DMT; however, aHSCT was found to be non-inferior to a newer high-efficacy DMT. Conclusion: all three studies demonstrated the efficacious benefits of aHSCT therapy for patients with highly active RRMS, though further research is required for more direct comparisons to mAbs more recently approved for RRMS.
